Vertex Pharmaceuticals Inc. buy stratec
Start price
14.01.18
/
50%
€142.77
Target price
11.01.19
€170.18
Performance (%)
18.71%
End price
11.01.19
€169.48
Summary
This prediction ended on 11.01.19 with a price of €169.48. The prediction had a final performance of 18.71%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 1.093% | 1.093% | 33.870% | 140.506% |
| iShares Core DAX® | -0.448% | 2.344% | 15.948% | 18.098% |
| iShares Nasdaq 100 | 0.834% | 5.019% | 30.983% | 56.534% |
| iShares Nikkei 225® | -0.479% | 0.550% | 9.206% | 5.013% |
| iShares S&P 500 | -0.352% | 2.631% | 26.224% | 46.697% |
Comments by stratec for this prediction
In the thread Vertex Pharmaceuticals Inc. diskutieren
Vertex wins expanded approval for its cystic fibrosis combo
Looking forward: VRTX moves the needle here with this approval. Now, it would appear as though the European approval matches that in America, and this can be a good tool for young patients with this form of cystic fibrosis. The $250,000+ price tag on Orkambi means that even with only reaching a third of the patients, the company stands to gain hundreds of millions in revenue a year from this.
stratec stimmt am 14.01.2018 der Outperform-Einschätzung der institutionellen Analysten aber mit dem Kursziel 188,67$ zu.
(Vom Mitglied beendet)